GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (NYSE:PBH) » Definitions » Equity-to-Asset

Prestige Consumer Healthcare (Prestige Consumer Healthcare) Equity-to-Asset

: 0.48 (As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Prestige Consumer Healthcare's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,601 Mil. Prestige Consumer Healthcare's Total Assets for the quarter that ended in Dec. 2023 was $3,340 Mil. Therefore, Prestige Consumer Healthcare's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.48.

The historical rank and industry rank for Prestige Consumer Healthcare's Equity-to-Asset or its related term are showing as below:

PBH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21   Med: 0.32   Max: 0.48
Current: 0.48

During the past 13 years, the highest Equity to Asset Ratio of Prestige Consumer Healthcare was 0.48. The lowest was 0.21. And the median was 0.32.

PBH's Equity-to-Asset is ranked worse than
63.2% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs PBH: 0.48

Prestige Consumer Healthcare Equity-to-Asset Historical Data

The historical data trend for Prestige Consumer Healthcare's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.33 0.40 0.43 0.43

Prestige Consumer Healthcare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.43 0.44 0.46 0.48

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prestige Consumer Healthcare Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Prestige Consumer Healthcare's Equity-to-Asset falls into.



Prestige Consumer Healthcare Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Prestige Consumer Healthcare's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=1447.084/3353.729
=0.43

Prestige Consumer Healthcare's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1600.577/3339.753
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prestige Consumer Healthcare  (NYSE:PBH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Prestige Consumer Healthcare Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Prestige Consumer Healthcare (Prestige Consumer Healthcare) Business Description

Traded in Other Exchanges
Address
660 White Plains Road, Tarrytown, NY, USA, 10591
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Executives
Mary Beth Fritz officer: Senior VP Quality & Regulatory 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Ronald M. Lombardi officer: Chief Executive Officer 660 WHITE PLAINS RD., TARRYTOWN NY 10591
James Darecca director C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Christine Sacco officer: Chief Financial Officer C/O SMART BALANCE, INC., 115 WEST CENTURY ROAD, SUITE 260, PARAMUS NJ 07652
Adel Mekhail other: EVP, Marketing & Sales 660 WHITE PLAINS RD., 2ND FL, TARRYTOWN NY 10591
William P'pool officer: See Remarks 2400 WEST LLOYD EXPRESSWAY, EVANSVILLE IL 47721
Celeste A. Clark director C/O ADVANCEPIERRE FOODS HOLDINGS, INC., 9987 CARVER ROAD, BLUE ASH OH 45242
Christopher J Coughlin director
Natale S Ricciardi director C/O MORRIS COMMUNICATIONS CORP, 725 BROAD ST., AUGUSTA GA 30903
James M Jenness director PO BOX 3599, BATTLECREEK MI 49016-3599
John E Byom director 660 WHITE PLAINS RD., TARRYTOWN NY 10591
Sheila Hopkins director C/O WARNACO INC, 90 PARK AVENUE, NEW YORK NY 10016
Dawn M. Zier director 600 OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Jeffrey Zerillo officer: Senior VP Operations 660 WHITE PLAINS RD, 2ND FL, TARRYTOWN NY 10591
Timothy Connors officer: Chief Marketing Officer 660 WHITE PLAINS RD., SUITE 205, TARRYTOWN NY 10591